Adaptive immunity in autoimmune hepatitis

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 63-69

  Longhi, Maria Serena ^a   Ma, Yun ^a   Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Autoimmune hepatitis; Interface hepatitis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CYTOCHROME P450 2D6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; AUTOIMMUNE HEPATITIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LIVER CELL; LIVER INJURY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE ACTIVATION; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; AUTOANTIBODIES; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; LYMPHOCYTES; MOLECULAR MIMICRY; T-LYMPHOCYTES, REGULATORY;

EID: 77952571694     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282066     Document Type: Review

References (47)

1. Donaldson PT: Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22:353-364.
2. Donaldson PT: Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol 2004;41:327-332.
3. Czaja AJ, Donaldson PT: Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-259.
4. Ma Y, Bogdanos DP, Hussain MJ, et al: Polyclonal T-cell responses to cytochrome P450I-ID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006;130:868-882.
5. Duarte-Rey C, Pardo AL, Rodriguez-Velosa Y, Mantilla RD, Anaya JM, Rojas-Villarraga A: HLA class II association with autoimmune hepatitis in Latin America: a meta-analysis. Autoimmun Rev 2009;8:325-331.
6. Agarwal K, Czaja AJ, Jones DE, Donaldson PT: Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31:49-53.
7. Bittencourt PL, Palacios SA, Cancado EL, et al: Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer susceptibility to autoimmune hepatitis types 1 and 2 in Brazil. Am J Gastroenterol 2003;98:1616-1620.
8. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT: Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645-652.
9. Yoshizawa K, Ota M, Katsuyama Y, et al: Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 2005;42:578-584.
10. Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D: Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 1992;67:1447-1453.
11. Lobo-Yeo A, Senaldi G, Portmann B, Mowat A P, Mieli-Vergani G, Vergani D: Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990;12:224-232.
12. Senaldi G, Lobo-Yeo A, Mowat AP, Mieli-Vergani G, Vergani D: Class I and class II major histocompatibility complex antigens on hepatocytes: importance of the method of detection and expression in histologically normal and diseased livers. J Clin Pathol 1991;44:107-114.
13. Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
14. Mieli-Vergani G, Vergani D, Jenkins PJ, et al: Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol 1979;38:16-21.
15. Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL: Immunoglobulin on the surface ofisolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 1987;7:307-315.
16. Jensen DM, McFarlane IG, Portmann BS, Eddleston AL, Williams R: Detection of antibodies directed against a liver-specific membra ne lipoprotei n in patients with acute and chronic active hepatitis. N Engl J Med 1978;299:1-7.
17. McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R: Serum autoantibodies reacting with the hepatic asialoglyco-protein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol 1986;3:196-205.
18. Ma Y, Gaken J, McFarlane BM, Foss Y, Farzaneh F, McFarlane IG, et al: Alcohol dehydrogenase: a target of humoral autoimmune response in liver disease. Gastroenterology 1997;112:483-492.
19. Palioura S, Sherrer RL, Steitz TA, Soll D, Simonovic M: The human SepSecS-tRNASec complex reveals the mechanism of seleno-cysteine formation. Science 2009;325:321-325.
20. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH: Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1:292-294.
21. Ma Y, Okamoto M, Thomas MG, et al: Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-664.
22. Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F: Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988;168:801-806.
23. Muratori L, Parola M, Ripalti A, et al: Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000;46:553-561.
24. Kerkar N, Choudhuri K, Ma Y, et al: Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003;170:1481-1489.
25. Ma Y, Thomas MG, Okamoto M, et al: Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol 2002;169:277-285.
26. Wen L, Peakman M, Lobo-Yeo A, et al: T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990;336:1527-1530.
27. Wen L, Ma Y, Bogdanos DP, et al: Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 2001;1:379-389.
28. Lohr H, Manns M, Kyriatsoulis A, et al: Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991;84:297-302.
29. Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde KH: Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialo-glycoprotein receptor in vitro. Clin Exp Immunol 1992;88:45-49.
30. Longhi MS, Hussain MJ, Bogdanos DP, et al: Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007;46:472-484.
31. Manns MP, Griffin KJ, Sullivan KF, Johnson EF: LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-1378.
32. Nouri-Aria KT, Hegarty JE, Alexander GJ, Eddleston AL, Williams R: Effect of cortico-steroids on suppressor-cell activity in 'autoimmune' and viral chronic active hepatitis. N Engl J Med 1982;307:1301-1304.
33. Vento S, Hegarty JE, Bottazzo G, Macchia E, Williams R, Eddleston AL: Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1984;1:1200-1204.
34. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D: Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004;41:31-37.
35. Longhi MS, Ma Y, Mitry RR, et al: Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005;25:63-71.
36. Longhi MS, Hussain MJ, Mitry RR, et al: Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176:4484-4491.
37. Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control ofimmune responses. Annu Rev Immunol 2004;22:531-562.
38. Longhi MS, Mitry RR, Samyn M, et al: Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009;50:130-142.
39. Riley JL, June CH, Blazar BR: Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009;30:656-665.
40. Longhi MS, Meda F, Wang P, et al: Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47:581-591.
41. Gregorio GV, Choudhuri K, Ma Y, Vegnente A, Mieli-Vergani G, Vergani D: Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. J Immunol 1999;162:1802-1810.
42. Gregorio GV, Choudhuri K, Ma Y, et al: Mimicry between the hepatitis C virus poly-protein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003;133:404-413.
43. Bortolotti F, Vajro P, Balli F, et al: Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996;25:614-620. (Pubitemid 26373875)
44. Lenzi M, Bellentani S, Saccoccio G, et al: Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999;45:435-441.
45. Bogdanos DP, Choudhuri K, Vergani D: Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001;21:225-232.
46. Mackie FD, Peakman M, Yun M, et al: Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 1994;106:1672-1675.
47. Agmon-Levin N, Ram M, Barzilai O, et al: Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun 2009;32:261-266.